What does this research mean for the field?

Pharmacotherapy for obstructive sleep apnea is advancing toward targeted, phenotype-driven personalized treatments, with multiple drug classes showing promise as alternatives or synergistic adjuncts to CPAP therapy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To summarize the pathophysiological rationale and evaluate recent developments in pharmacological interventions for obstructive sleep apnea.

August 23, 2026Journal of Clinical MedicineOpen Access

Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments

View Full Paper

Ask AI

Bookmark

Authors

RZRuobing Zhou GYGe Yin YZYun Zhu

Discussion

Member takes

Overview

Narrative review outlines emerging targeted drug therapies for obstructive sleep apnea, suggesting potential for personalized alternatives or combination approaches to mechanical positive airway...

Key Points

To summarize the pathophysiological rationale and evaluate recent developments in pharmacological interventions for obstructive sleep apnea.
Conducted a narrative review with systematic literature searches of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to August 2026.
Synthesized evidence from randomized controlled trials, observational studies, meta-analyses, and mechanistic human or animal studies, applying GRADE principles.
Identified promising drug classes targeting distinct mechanisms, including upper-airway dilator muscle activators, respiratory stabilizers that reduce loop gain, arousal threshold modulators, mucosal anti-inflammatory agents, and incretin receptor agonists.
Preclinical gene therapies targeting the hypoglossal motor system and multi-modal combinations with continuous positive airway pressure demonstrate potential to improve tolerability and lower required therapeutic pressures.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/6a8aade47677a341144465ae https://doi.org/10.3390/jcm15166473

View Full Paper

Ask AI

Bookmark

August 23, 2026Journal of Clinical MedicineOpen Access

Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments

View Full Paper

Ask AI

Bookmark

Authors

RZRuobing Zhou GYGe Yin YZYun Zhu

Discussion

Member takes

Overview

Narrative review outlines emerging targeted drug therapies for obstructive sleep apnea, suggesting potential for personalized alternatives or combination approaches to mechanical positive airway...

Key Points

To summarize the pathophysiological rationale and evaluate recent developments in pharmacological interventions for obstructive sleep apnea.
Conducted a narrative review with systematic literature searches of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to August 2026.
Synthesized evidence from randomized controlled trials, observational studies, meta-analyses, and mechanistic human or animal studies, applying GRADE principles.
Identified promising drug classes targeting distinct mechanisms, including upper-airway dilator muscle activators, respiratory stabilizers that reduce loop gain, arousal threshold modulators, mucosal anti-inflammatory agents, and incretin receptor agonists.
Preclinical gene therapies targeting the hypoglossal motor system and multi-modal combinations with continuous positive airway pressure demonstrate potential to improve tolerability and lower required therapeutic pressures.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/6a8aade47677a341144465ae https://doi.org/10.3390/jcm15166473

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark